• The license agreement complements the collaboration between MedinCell and the health agency Unitaid, which is funding the development of the mdc-STM program, an experimental long-lasting injectable formulation for the prevention of malaria.
• Medicines Patent Pool (MPP) is a United Nations-supported public health organization whose mission is to improve access to essential medicines in low- and middle-income countries, and to facilitate the development of such medicines. medications.
• The license agreement relates to an injectable formulation of ivermectin with a duration of action of 3 months, using BEPO® technology from MedinCell, to fight against the transmission of malaria.
• The license agreement aims to ensure that the product will be widely distributed in low- and middle-income countries if it proves effective and safe.
• Still endemic in 91 countries, malaria caused 627,000 deaths in 2020. Children under 5 are the most vulnerable, accounting for 80% of deaths.
To receive all of MedinCell’s financial information in real time, send a request by email to [email protected]. Your registration will be immediate.